The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”), is an international consortium dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.
Latest News
Diagnosed with lung cancer before age 40? Help researchers crack the code! Sign up for Epidemiology of Young Lung Cancer. More research + more knowledge leads to new treatments and a cure. READ MORE
Genomics of Young Lung Cancer ALCMI Study Published ALCMI's GOYLC study has been published in JTO Clinical and Research Reports. Click here to read the full text article. READ MORE
Epidemiology of Young Lung Cancer This study seeks to help better understand why an increasing number of young people are developing lung cancer. Specifically, we are looking to study the environmental and childhood exposures, and other risk factors for lung cancer in persons under age 40. READ MORE
Diagnosed with lung cancer before age 40? Help researchers crack the code! Sign up for Epidemiology of Young Lung Cancer. More research + more knowledge leads to new treatments and a cure. READ MOREGenomics of Young Lung Cancer ALCMI Study Published ALCMI's GOYLC study has been published in JTO Clinical and Research Reports. Click here to read the full text article. READ MOREFirst Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker Study will evaluate the use of a blood-based biomarker to predict outcomes in high PD-L1 expressing non-small cell lung cancer patients treated with immune checkpoint inhibitors plus or minus chemotherapy READ MORE
Epidemiology of Young Lung Cancer This study seeks to help better understand why an increasing number of young people are developing lung cancer. Specifically, we are looking to study the environmental and childhood exposures, and other risk factors for lung cancer in persons under age 40. READ MORE